A Comprehensive Review of Spinal Muscular Atrophy (Sma): Treatment Strategies

Spinal muscular atrophy (SMA), a rare genetic disorder causing progressive muscle weakness due to SMN1 gene mutations, affects approximately 1 in 10,000 live births and historically lacked disease-modifying treatments. The approval of Spinraza (nusinersen) with the aid of the FDA in 2016 marked a paradigm shift because the first therapy for SMA, leveraging antisense oligonucleotide (ASO) technology to decorate SMN protein production via SMN2 gene splicing. Developed by Ionis Pharmaceuticals and marketed by Biogen, Spinraza has demonstrated significant efficacy across SMA types, with clinical trials like ENDEAR and CHERISH showing motor milestone achievements and survival benefits, particularly with early intervention. Its safety profile is favorable, though intrathecal administration poses challenges. Regulatory incentives under the Orphan Drug Act expedited its approval, yet its high cost—$750,000 for the first year— raises access and ethical concerns. Compared to emerging therapies like Zolgensma (gene therapy) and Evrysdi (oral small molecule), Spinraza offers broad applicability but requires repeated dosing. Patient and caregiver experiences highlight improved quality of life alongside logistical burdens, while real-world data as of April 05, 2025, affirm long-term benefits. This review synthesizes Spinraza’s mechanism, clinical outcomes, pharmacokinetics, regulatory journey, economic implications, and future directions, positioning it as a cornerstone of precision medicine for rare diseases. Despite its transformative impact, equitable access remains a critical challenge, underscoring the need for policy innovation to maximize its global reach.